TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s
Participants also experienced a VR-enabled learning environment designed to support clinical skill development in controlled, repeatable, and risk-free settings
Former Interim CEO takes charge to drive strategic growth, strengthen clinical excellence, and advance patient-centric oncology innovation
Subscribe To Our Newsletter & Stay Updated
